35 results on '"Olde Rikkert, Marcel"'
Search Results
2. Prognostic Information on Progression to Dementia: Quantification of the Impact on Quality of Life.
- Author
-
Vermeulen, Robin Jeanna, Roudijk, Bram, Govers, Tim Martin, Rovers, Maroeska Mariet, Olde Rikkert, Marcel Gerardus Maria, and Wijnen, Ben Franciscus Martinus
- Subjects
MILD cognitive impairment ,DEMENTIA ,QUALITY of life ,DISEASE risk factors ,LOGISTIC regression analysis ,ALZHEIMER'S disease ,VASCULAR dementia - Abstract
Background: The increasing interest in early identification of people at risk of developing dementia, has led to the development of numerous models aimed at estimating the likelihood of progression from mild cognitive impairment (MCI) to dementia. It is important to study both the need for and possible outcomes related with such prediction models, including the impact of risk predictions on perceived quality of life (QoL). Objective: This study aimed to quantify the impact that receiving a risk prediction on progression from MCI to dementia has on QoL. Methods: A Discrete Choice Experiment (DCE) and Time Trade Off (TTO) study were performed. Participants completed choice tasks related to dementia prognosis while imagining having MCI. We collected DCE data by an online survey, and TTO data via videoconferencing interviews. DCE data were analyzed using a mixed multinomial logit model and were anchored to a health state utility scale using mean observed TTO valuations. Results: 296 people participated in the DCE and 42 in the TTO. Moderate and high predicted dementia risks were associated with decrements in utility (–0.05 and –0.18 respectively), compared to no prognostic information. Low predicted risk was associated with an increase in utility (0.06), as well as the availability of medication or lifestyle interventions (0.05 and 0.13 respectively). Conclusions: This study shows a significant impact of dementia risk predictions on QoL and highlights the importance of caution when sharing information about expected MCI disease courses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Effects of long-term sleep disruption on cognitive function and brain amyloid-β burden: a case-control study
- Author
-
Thomas, Jana, Ooms, Sharon J., Mentink, Lara J., Booij, Jan, Olde Rikkert, Marcel G. M., Overeem, Sebastiaan, Kessels, Roy P. C., and Claassen, Jurgen A. H. R.
- Published
- 2020
- Full Text
- View/download PDF
4. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
- Author
-
Bos, Isabelle, Verhey, Frans R., Ramakers, Inez H.G.B., Jacobs, Heidi I. L., Soininen, Hilkka, Freund-Levi, Yvonne, Hampel, Harald, Tsolaki, Magda, Wallin, Åsa K., van Buchem, Mark A., Oleksik, Ania, Verbeek, Marcel M., Olde Rikkert, Marcel, van der Flier, Wiesje M., Scheltens, Philip, Aalten, Pauline, Visser, Pieter Jelle, and Vos, Stephanie J. B.
- Published
- 2017
- Full Text
- View/download PDF
5. Population Attributable Fractions for Modifiable Risk Factors of Incident Dementia in Cognitively Normal and Mild Cognitively Impaired Older Adults: Data from Two Cohort Studies.
- Author
-
Wezeman, Sandra L., Uleman, Jeroen F., Scarmeas, Nikolaos, Kosmidis, Mary H., Dardiotis, Efthimios, Peeters, G.M.E.E., Olde Rikkert, Marcel G.M., and Peeters, G M E E Geeske
- Subjects
ALZHEIMER'S disease ,DEMENTIA ,MILD cognitive impairment ,DISEASE risk factors ,ADULTS ,DISEASE progression ,RESEARCH ,META-analysis ,RESEARCH methodology ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,LONGITUDINAL method ,PROPORTIONAL hazards models - Abstract
Background: Recent global meta-analyses show that 40% of dementia cases can be attributed to twelve modifiable risk factors.Objective: To investigate how health promotion strategies may differ in specific populations, this study estimated population attributable fractions (PAFs) of these risk factors for dementia in cognitively normal (CN) individuals and individuals with mild cognitive impairment (MCI) in United States and Greek cohorts.Methods: We re-analyzed data from the National Alzheimer's Coordinating Centre (NACC, n = 16,147, mean age 75.2±6.9 years, 59.0% female) and the Hellenic Longitudinal Investigation of Aging and Diet (HELIAD, n = 1,141, mean age 72.9±5.0 years, 58.0% female). PAFs for the total samples and CN and MCI subgroups were calculated based on hazard ratios for the risk of dementia and risk factor prevalence in NACC (9 risk factors) and HELIAD (10 risk factors).Results: In NACC, 2,630 participants developed MCI (25.1%) and 3,333 developed dementia (20.7%) during a mean follow-up of 4.9±3.5 years. Weighted overall PAFs were 19.4% in the total sample, 15.9% in the CN subgroup, and 3.3% in the MCI subgroup. In HELIAD, 131 participants developed MCI (11.2%) and 68 developed dementia (5.9%) during an average follow-up of 3.1±0.86 years. Weighted overall PAFs were 65.5% in the total sample, 65.8% in the CN subgroup and 64.6% in the MCI subgroup.Conclusion: Translation of global meta-analysis data on modifiable risk factors should be carefully carried out per population. The PAFs of risk factors differ substantially across populations, directing health policy making to tailored risk factor modification plans. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. NeuroExercise: The Effect of a 12-Month Exercise Intervention on Cognition in Mild Cognitive Impairment—A Multicenter Randomized Controlled Trial.
- Author
-
Stuckenschneider, Tim, Sanders, Marit L., Devenney, Kate E., Aaronson, Justine A., Abeln, Vera, Claassen, Jurgen A. H. R., Guinan, Emer, Lawlor, Brian, Meeusen, Romain, Montag, Christian, Olde Rikkert, Marcel G. M., Polidori, M. Cristina, Reuter, Martin, Schulz, Ralf-Joachim, Vogt, Tobias, Weber, Bernd, Kessels, Roy P. C., and Schneider, Stefan
- Subjects
MILD cognitive impairment ,AEROBIC exercises ,EXERCISE ,CLINICAL trial registries ,PHYSICAL fitness - Abstract
Exercise intervention studies in mild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease (AD), have demonstrated inconsistent yet promising results. Addressing the limitations of previous studies, this trial investigated the effects of a 12-month structured exercise program on the progression of MCI. The NeuroExercise study is a multicenter randomized controlled trial across three European countries (Ireland, Netherlands, Germany). Hundred and eighty-three individuals with amnestic MCI were included and were randomized to a 12-month exercise intervention (3 units of 45 min) of either aerobic exercise (AE; n = 60), stretching and toning exercise (ST; n = 65) or to a non-exercise control group (CG; n = 58). The primary outcome, cognitive performance, was determined by an extensive neuropsychological test battery. For the primary complete case (CC) analyses, between-group differences were analyzed with analysis of covariance under two conditions: (1) the exercise group (EG = combined AE and ST groups) compared to the CG and (2) AE compared to ST. Primary analysis of the full cohort (n = 166, 71.5 years; 51.8% females) revealed no between-group differences in composite cognitive score [mean difference (95% CI)], 0.12 [(−0.03, 0.27), p = 0.13] or in any cognitive domain or quality of life. VO
2 peak was significantly higher in the EG compared to the CG after 12 months [−1.76 (−3.39, −0.10), p = 0.04]. Comparing the two intervention groups revealed a higher VO2 peak level in the aerobic exercise compared to the stretching and toning group, but no differences for the other outcomes. A 12-month exercise intervention did not change cognitive performance in individuals with amnestic MCI in comparison to a non-exercise CG. An intervention effect on physical fitness was found, which may be an important moderator for long term disease progression and warrants long-term follow-up investigations. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT02913053, identifier: NCT02913053. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. Home-EEG assessment of possible compensatory mechanisms for sleep disruption in highly irregular shift workers – The ANCHOR study.
- Author
-
Mentink, Lara J., Thomas, Jana, Melis, René J. F., Olde Rikkert, Marcel G. M., Overeem, Sebastiaan, and Claassen, Jurgen A. H. R.
- Subjects
MARITIME pilots ,MULTILEVEL models ,ALZHEIMER'S disease ,SHIFT systems ,SLEEP - Abstract
Study objectives: While poor sleep quality has been related to increased risk of Alzheimer's disease, long-time shift workers (maritime pilots) did not manifest evidence of early Alzheimer's disease in a recent study. We explored two hypotheses of possible compensatory mechanisms for sleep disruption: Increased efficiency in generating deep sleep during workweeks (model 1) and rebound sleep during rest weeks (model 2). Methods: We used data from ten male maritime pilots (mean age: 51.6±2.4 years) with a history of approximately 18 years of irregular shift work. Subjective sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI). A single lead EEG-device was used to investigate sleep in the home/work environment, quantifying total sleep time (TST), deep sleep time (DST), and deep sleep time percentage (DST%). Using multilevel models, we studied the sleep architecture of maritime pilots over time, at the transition of a workweek to a rest week. Results: Maritime pilots reported worse sleep quality in workweeks compared to rest weeks (PSQI = 8.2±2.2 vs. 3.9±2.0; p<0.001). Model 1 showed a trend towards an increase in DST% of 0.6% per day during the workweek (p = 0.08). Model 2 did not display an increase in DST% in the rest week (p = 0.87). Conclusions: Our findings indicated that increased efficiency in generating deep sleep during workweeks is a more likely compensatory mechanism for sleep disruption in the maritime pilot cohort than rebound sleep during rest weeks. Compensatory mechanisms for poor sleep quality might mitigate sleep disruption-related risk of developing Alzheimer's disease. These results should be used as a starting point for future studies including larger, more diverse populations of shift workers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Orthostatic Blood Pressure Recovery Is Associated With the Rate of Cognitive Decline and Mortality in Clinical Alzheimer’s Disease.
- Author
-
de Heus, Rianne A. A., de Jong, Daan. L. K., Rijpma, Anne, Lawlor, Brian A., Olde Rikkert, Marcel G. M., and Claassen, Jurgen A. H. R.
- Abstract
Background: Impaired recovery of blood pressure (BP) after standing has been shown to be related to cognitive function and mortality in people without dementia, but its role in people with Alzheimer's disease (AD) is unknown. The aim of this study was to investigate the association of the orthostatic BP response with cognitive decline and mortality in AD. Methods: In this post hoc analysis of a randomized controlled trial (Nilvad), we measured the beat-to-beat response of BP upon active standing in mild-to-moderate AD. This included the initial drop (nadir within 40 seconds) and recovery after 1 minute, both expressed relative to resting values. We examined the relationship between a small or large initial drop (median split) and unimpaired (≥100%) or impaired recovery (<100%) with 1.5-year change in Alzheimer's Disease Assessment-cognitive subscale (ADAS-cog) scores and all-cause mortality. Results: We included 55 participants (age 73.1 ± 6.2 years). Impaired BP recovery was associated with higher increases in ADAS-cog scores (systolic: β [95% confidence interval] = 5.6 [0.4-10.8], p = .035; diastolic: 7.6 [2.3-13.0], p = .006). During a median follow-up time of 49 months, 20 participants died. Impaired BP recovery was associated with increased mortality (systolic: HR [95% confidence interval] = 2.9 [1.1-7.8], p = .039; diastolic: HR [95% confidence interval] = 5.5 [1.9-16.1], p = .002). The initial BP drop was not associated with any outcome. Results were adjusted for age, sex, and intervention group. Conclusions: Failure to fully recover BP after 1 minute of standing is associated with cognitive decline and mortality in AD. As such, BP recovery can be regarded as an easily obtained marker of progression rate of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD.
- Author
-
Dyer, Adam H., Lawlor, Brian, Kennelly, Sean P., for the NILVAD Study Group, Segurado, Ricardo, Kennelly, Sean, Olde Rikkert, Marcel G. M., Howard, Robert, Pasquier, Florence, Bor¨jesson-Hanson, Anne, Tsolaki, Magda, Lucca, Ugo, Molloy, D. William, Coen, Robert, Riepe, Matthias W., Ka'lma'n, Ja'nos, Kenny, Rose Anne, Cregg, Fiona, O'Dwyer, Sarah, and Walsh, Cathal
- Subjects
WALKING speed ,ALZHEIMER'S disease ,COGNITION disorders ,OLDER people ,COGNITION - Abstract
Background: Previous evidence suggests that slower gait speed is longitudinally associated with cognitive impairment, dementia and falls in older adults. Despite this, the longitudinal relationship between gait speed, cognition and falls in those with a diagnosis of dementia remains poorly explored. We sought to assess this longitudinal relationship in a cohort of older adults with mild to-moderate Alzheimer Disease (AD).Methods: Analysis of data from NILVAD, an 18-month randomised-controlled trial of Nilvadipine in mild to moderate AD. We examined: (i) the cross-sectional (baseline) association between slow gait speed and cognitive function, (ii) the relationship between baseline slow gait speed and cognitive function at 18 months (Alzheimer Disease Assessment Scale, Cognitive Subsection: ADAS-Cog), (iii) the relationship between baseline cognitive function and incident slow gait speed at 18 months and finally (iv) the relationship of baseline slow gait speed and incident falls over the study period.Results: Overall, one-tenth (10.03%, N = 37/369) of participants with mild-to-moderate AD met criteria for slow gait speed at baseline and a further 14.09% (N = 52/369) developed incident slow gait speed at 18 months. At baseline, there was a significant association between poorer cognition and slow gait speed (OR 1.05, 95% CI 1.01-1.09, p = 0.025). Whilst there was no association between baseline slow gait speed and change in ADAS-Cog score at 18 months, a greater cognitive severity at baseline predicted incident slow gait speed over 18 months (OR 1.04, 1.01-1.08, p = 0.011). Further, slow gait speed at baseline was associated with a significant risk of incident falls over the study period, which persisted after covariate adjustment (IRR 3.48, 2.05-5.92, p < 0.001).Conclusions: Poorer baseline cognition was associated with both baseline and incident slow gait speed. Slow gait speed was associated with a significantly increased risk of falls over the study period. Our study adds further evidence to the complex relationship between gait and cognition in this vulnerable group and highlights increased falls risk in older adults with AD and slow gait speed.Trial Registration: Secondary analysis of the NILVAD trial (Clincaltrials.gov NCT02017340; EudraCT number 2012-002764-27). First registered: 20/12/2013. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. Individual Differences in the Effects of Physical Activity on Cognitive Function in People with Mild to Moderate Dementia.
- Author
-
Uijen, Iris L., Aaronson, Justine A., Karssemeijer, Esther G.A., Olde Rikkert, Marcel G.M., Kessels, Roy P.C., and Küster, Olivia
- Subjects
PHYSICAL activity ,COGNITIVE ability ,EPISODIC memory ,INDIVIDUAL differences ,DEMENTIA ,ALZHEIMER'S disease ,ALZHEIMER'S disease treatment ,EXERCISE & psychology ,TREATMENT of dementia ,EXECUTIVE function ,MEMORY ,RESEARCH ,RESEARCH methodology ,COGNITION ,INDIVIDUALITY ,MEDICAL cooperation ,EVALUATION research ,TREATMENT effectiveness ,COMPARATIVE studies ,BLIND experiment ,APOLIPOPROTEINS ,SHORT-term memory ,REACTION time - Abstract
The aim of this study was to investigate whether the effect of physical activity on cognitive function in persons with dementia is moderated by patient characteristics as Apolipoprotein E and dementia type. We included 101 individuals with dementia and calculated the reliable change index to determine the change in global cognition, executive function, episodic memory, working memory, and processing speed before and after a 12-week exercise training. We found a higher treatment-related benefit in episodic memory in persons with non-Alzheimer's disease compared to persons with Alzheimer's disease, and in executive function in individuals with better baseline cognitive function. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
- Author
-
Abdullah, Laila, Crawford, Fiona, Tsolaki, Magda, Börjesson-Hanson, Anne, Olde Rikkert, Marcel, Pasquier, Florence, Wallin, Anders, Kennelly, Sean, Ait-Ghezala, Ghania, Paris, Daniel, Hendrix, Suzanne, Blennow, Kaj, Lawlor, Brian, and Mullan, Michael
- Subjects
ALZHEIMER'S disease ,CALCIUM antagonists ,CEREBROSPINAL fluid ,TREATMENT effectiveness ,BIOLOGICAL tags - Abstract
We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity. Exploratory analyses were performed on the dataset (n = 497) of a phase III randomized placebo-controlled trial to examine the response to nilvadipine in AD subjects stratified by baseline AD severity into very mild (MMSE ≥ 25), mild (MMSE 20-24) and moderate AD (MMSE < 20). The outcome measures included total and subscale scores of the Alzheimer's Disease Assessment Scale Cognitive 12 (ADAS-Cog 12), the Clinical Dementia Rating Scale sum of boxes (CDR-sb) and the AD composite score (ADCOMS). Cerebrospinal fluid biomarkers Aβ38, Aβ40, Aβ42, neurofilament light chain (NFL), neurogranin, YKL-40, total tau and P181 tau (ptau) were measured in a subset of samples (n = 55). Regression analyses were adjusted for confounders to specifically examine the influence of nilvadipine and baseline AD severity on cognitive outcomes over 78-weeks. Compared to their respective placebo-controls, nilvadipine-treated, very mild AD subjects showed less decline, whereas moderate AD subjects showed a greater cognitive decline on the ADAS-Cog 12 test and the ADCOMS. A lower decline was observed after nilvadipine treatment for a composite memory trait in very mild AD subjects and a composite language trait in mild AD subjects. Cerebrospinal fluid Aβ42/Aβ40 ratios were increased in mild AD and decreased in moderate AD patients treated with nilvadipine, compared to their respective controls. Among moderate AD subjects, levels of ptau, total tau, neurogranin and YKL-40 increased in subjects treated with nilvadipine compared to placebo. These studies suggest that baseline AD severity influenced the treatment outcome in the NILVAD trial and that future clinical trials of nilvadipine should be restricted to mild and very mild AD patients. Trial Registration: NCT02017340 Registered 20 December 2013, https://clinicaltrials.gov/ct2/show/NCT02017340 EUDRACT Reference Number 2012-002764-27 Registered 04 February 2013, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease.
- Author
-
van de Beek, Marleen, van Steenoven, Inger, Ramakers, Inez H.G.B., Aalten, Pauline, Koek, Huiberdina L., Olde Rikkert, Marcel G.M., Manniën, Judith, Papma, Janne M., de Jong, Frank Jan, Lemstra, Afina W., and van der Flier, Wiesje M.
- Subjects
LEWY body dementia ,ALZHEIMER'S disease ,GERIATRIC Depression Scale ,QUALITY of life ,COGNITIVE testing - Abstract
Background: Quality of Life (QoL) is an important outcome measure in dementia, particularly in the context of interventions. Research investigating longitudinal QoL in dementia with Lewy bodies (DLB) is currently lacking.Objective: To investigate determinants and trajectories of QoL in DLB compared to Alzheimer's disease (AD) and controls.Methods: QoL was assessed annually in 138 individuals, using the EQ5D-utility-score (0-100) and the health-related Visual Analogue Scale (VAS, 0-100). Twenty-nine DLB patients (age 69±6), 68 AD patients (age 70±6), and 41 controls (age 70±5) were selected from the Dutch Parelsnoer Institute-Neurodegenerative diseases and Amsterdam Dementia Cohort. We examined clinical work-up over time as determinants of QoL, including cognitive tests, neuropsychiatric inventory, Geriatric Depression Scale (GDS), and disability assessment of dementia (DAD).Results: Mixed models showed lower baseline VAS-scores in DLB compared to AD and controls (AD: β±SE = -7.6±2.8, controls: β±SE = -7.9±3.0, p < 0.05). An interaction between diagnosis and time since diagnosis indicated steeper decline on VAS-scores for AD patients compared to DLB patients (β±SE = 2.9±1.5, p < 0.1). EQ5D-utility-scores over time did not differ between groups. Higher GDS and lower DAD-scores were independently associated with lower QoL in dementia patients (GDS: VAS β±SE = -1.8±0.3, EQ5D-utility β±SE = -3.7±0.4; DAD: VAS = 0.1±0.0, EQ5D-utility β±SE = 0.1±0.1, p < 0.05). No associations between cognitive tests and QoL remained in the multivariate model.Conclusion: QoL is lower in DLB, while in AD QoL shows steeper decline as the disease advances. Our results indicate that non-cognitive symptoms, more than cognitive symptoms, are highly relevant as they impact QoL. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
13. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
- Author
-
Lawlor, Brian, Segurado, Ricardo, Kennelly, Sean, Olde Rikkert, Marcel G. M., Howard, Robert, Pasquier, Florence, Börjesson-Hanson, Anne, Tsolaki, Magda, Lucca, Ugo, Molloy, D. William, Coen, Robert, Riepe, Matthias W., Kálmán, János, Kenny, Rose Anne, Cregg, Fiona, O'Dwyer, Sarah, Walsh, Cathal, Adams, Jessica, Banzi, Rita, and Breuilh, Laetitia
- Subjects
REHABILITATION centers ,ALZHEIMER'S disease ,EMERGENCY medical services ,RANDOMIZED controlled trials ,MENTAL health services - Abstract
Background: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease.Methods and Findings: NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23 academic centres in nine European countries. Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged >50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of ≥12 and <27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo. The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADAS-Cog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 weeks, 6.41 (5.33-7.49) at 52 weeks, and 9.63 (8.33-10.93) at 78 weeks and on nilvadipine was 0.88 (0.02-1.74) at 13 weeks, 5.75 (4.66-6.85) at 52 weeks, and 9.41 (8.09-10.73) at 78 weeks. Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of AEs. Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid.Conclusions: The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease.Trial Registration: Clinicaltrials.gov NCT02017340, EudraCT number 2012-002764-27. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes.
- Author
-
Haaksma, Miriam L., Calderón-Larrañaga, Amaia, Olde Rikkert, Marcel G. M., Melis, René J. F., Leoutsakos, Jeannie‐Marie S., and Leoutsakos, Jeannie-Marie S
- Subjects
ALZHEIMER'S disease ,MENTAL illness ,LOGISTIC regression analysis ,DEMENTIA ,MENTAL health - Abstract
Objective: We sought to replicate a previously published prediction model for progression, developed in the Cache County Dementia Progression Study, using a clinical cohort from the National Alzheimer's Coordinating Center.Methods: We included 1120 incident Alzheimer disease (AD) cases with at least one assessment after diagnosis, originating from 31 AD centres from the United States. Trajectories of the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating sum of boxes (CDR-sb) were modelled jointly over time using parallel-process growth mixture models in order to identify latent classes of trajectories. Bias-corrected multinomial logistic regression was used to identify baseline predictors of class membership and compare these with the predictors found in the Cache County Dementia Progression Study.Results: The best-fitting model contained 3 classes: Class 1 was the largest (63%) and showed the slowest progression on both MMSE and CDR-sb; classes 2 (22%) and 3 (15%) showed moderate and rapid worsening, respectively. Significant predictors of membership in classes 2 and 3, relative to class 1, were worse baseline MMSE and CDR-sb, higher education, and lack of hypertension. Combining all previously mentioned predictors yielded areas under the receiver operating characteristic curve of 0.70 and 0.75 for classes 2 and 3, respectively, relative to class 1.Conclusions: Our replication study confirmed that it is possible to predict trajectories of progression in AD with relatively good accuracy. The class distribution was comparable with that of the original study, with most individuals being members of a class with stable or slow progression. This is important for informing newly diagnosed AD patients and their caregivers. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
15. The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial.
- Author
-
Rijpma, Anne, van der Graaf, Marinette, Lansbergen, Marieke M., Meulenbroek, Olga, Cetinyurek-Yavuz, Aysun, Sijben, John W., Heerschap, Arend, and Olde Rikkert, Marcel G. M.
- Subjects
ELEMENTAL diet ,PHOSPHOLIPIDS ,LIPID metabolism ,ALZHEIMER'S disease ,PROTON magnetic resonance spectroscopy - Abstract
Background: Synaptic dysfunction contributes to cognitive impairment in Alzheimer's disease and may be countered by increased intake of nutrients that target brain phospholipid metabolism. In this study, we explored whether the medical food Souvenaid affects brain phospholipid metabolism in patients with Alzheimer's disease. Methods: Thirty-four drug-naive patients with mild Alzheimer's disease (Mini Mental State Examination score =20) were enrolled in this exploratory, double-blind, randomized controlled study. Before and after 4-week intervention with Souvenaid or an isocaloric control product, phosphorus and proton magnetic resonance spectroscopy (MRS) was performed to assess surrogate measures of phospholipid synthesis and breakdown (phosphomonoesters [PME] and phosphodiesters [PDEs]), neural integrity (N-acetyl aspartate), gliosis (myo-inositol), and choline metabolism (cholinecontaining compounds [tCho]). The main outcome parameters were PME and PDE signal intensities and the PME/PDE ratio. Results: MRS data from 33 patients (60-86 years old; 42% males; Souvenaid arm n = 16; control arm n = 17) were analyzed. PME/PDE and tCho were higher after 4 weeks of Souvenaid compared with control (PME/PDE least squares [LS] mean difference [95% CI] 0.18 [0.06-0.30], p = 0.005; tCho LS mean difference [95% CI] 0.01 [0.00-0.02], p = 0.019). No significant differences were observed in the other MRS outcome parameters. Conclusions: MRS reveals that Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease, in line with findings in preclinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study.
- Author
-
Hooghiemstra, Astrid M., Ramakers, Inez H. G. B., Sistermans, Nicole, Pijnenburg, Yolande A. L., Aalten, Pauline, Hamel, Renske E. G., Melis, René J. F., Verhey, Frans R. J., Olde Rikkert, Marcel G. M., Scheltens, Philip, van der Flier, Wiesje M., and 4C Study Group
- Subjects
FRAGILITY (Psychology) ,COGNITIVE ability ,PERSEVERATION (Psychology) ,CRYSTALLIZED intelligence ,ALZHEIMER'S disease ,ALZHEIMER'S disease treatment ,DEMENTIA ,PROGNOSIS ,COMPARATIVE studies ,GAIT in humans ,GRIP strength ,LONGITUDINAL method ,NEUROPSYCHOLOGICAL tests ,RESEARCH methodology ,MEDICAL cooperation ,PSYCHOLOGICAL tests ,REGRESSION analysis ,RESEARCH ,EVALUATION research ,DISEASE progression ,EXECUTIVE function - Abstract
Background: Prospective studies in the general population show that slow gait speed is associated with cognitive decline and clinical progression to dementia. However, longitudinal studies in memory clinic populations are mostly lacking. We aimed to study the association between gait speed and grip strength and cognitive functioning at baseline and cognitive decline over time in memory clinic patients with subjective cognitive decline and mild cognitive impairment.Methods: We included 309 patients (age 70 ± 9 years, 108 [35%] women, Mini-Mental State Examination 27 ± 3 points). Baseline gait speed was assessed over 15 feet, grip strength with a hydraulic hand dynamometer. Cognitive functioning was assessed annually with a comprehensive test battery during 3 years.Results: Age- and gender-adjusted linear mixed models showed that slower gait speed was related to worse baseline attention, memory, information processing speed, and verbal fluency. Longitudinally, gait speed was related to decline in information processing speed and executive functioning. Weaker grip strength was related to worse baseline information processing speed and executive functioning but there were no longitudinal associations. Cox proportional hazards models revealed no significant associations with clinical progression.Conclusions: Our findings suggest that markers of physical performance are related to current cognitive status and modestly related to cognitive decline but are seemingly not useful as an early marker of incident clinical progression. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. Comorbidity and progression of late onset Alzheimer’s disease: A systematic review.
- Author
-
Haaksma, Miriam L., Vilela, Lara R., Marengoni, Alessandra, Calderón-Larrañaga, Amaia, Leoutsakos, Jeannie-Marie S., Olde Rikkert, Marcel G. M., and Melis, René J. F.
- Subjects
ALZHEIMER'S disease ,BASAL ganglia diseases ,PRESENILE dementia ,NEURODEGENERATION ,DEGENERATION (Pathology) - Abstract
Background: Alzheimer’s disease is a neurodegenerative syndrome characterized by multiple dimensions including cognitive decline, decreased daily functioning and psychiatric symptoms. This systematic review aims to investigate the relation between somatic comorbidity burden and progression in late-onset Alzheimer’s disease (LOAD). Methods: We searched four databases for observational studies that examined cross-sectional or longitudinal associations of cognitive or functional or neuropsychiatric outcomes with comorbidity in individuals with LOAD. From the 7966 articles identified originally, 11 studies were included in this review. The Newcastle-Ottawa quality assessment was used. The large variation in progression measures, comorbidity indexes and study designs hampered the ability to perform a meta-analysis. This review was registered with PROSPERO under DIO: 10.15124/CRD42015027046. Results: Nine studies indicated that comorbidity burden was associated with deterioration in at least one of the three dimensions of LOAD examined. Seven out of ten studies investigating cognition found comorbidities to be related to decreased cognitive performance. Five out of the seven studies investigating daily functioning showed an association between comorbidity burden and decreased daily functioning. Neuropsychiatric symptoms (NPS) increased with increasing comorbidity burden in two out of three studies investigating NPS. Associations were predominantly found in studies analyzing the association cross-sectionally, in a time-varying manner or across short follow-up (≤2 years). Rarely baseline comorbidity burden appeared to be associated with outcomes in studies analyzing progression over longer follow-up periods (>2 years). Conclusion: This review provides evidence of an association between somatic comorbidities and multifaceted LOAD progression. Given that time-varying comorbidity burden, but much less so baseline comorbidity burden, was associated with the three dimensions prospectively, this relationship cannot be reduced to a simple cause-effect relation and is more likely to be dynamic. Therefore, both future studies and clinical practice may benefit from regarding comorbidity as a modifiable factor with a possibly fluctuating influence on LOAD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning.
- Author
-
Voigt-Radloff, Sebastian, de Werd, Maartje M. E., Leonhart, Rainer, Boelen, Danielle H. E., Olde Rikkert, Marcel G. M., Fliessbach, Klaus, Klöppel, Stefan, Heimbach, Bernhard, Fellgiebel, Andreas, Dodel, Richard, Eschweiler, Gerhard W., Hausner, Lucrezia, Kessels, Roy P. C., and Hüll, Michael
- Subjects
DEMENTIA patients ,ALZHEIMER'S disease ,BASAL ganglia diseases ,RANDOMIZED controlled trials ,DISCOVERY method (Teaching) - Abstract
Background: Errorless learning (EL) is a method for optimizing learning, which uses feed-forward instructions in order to prevent people from making mistakes during the learning process. The majority of previous studies on EL taught patients with dementia artificial tasks of little or no relevance for their daily lives. Furthermore, only a few controlled studies on EL have so far been performed and just a handful of studies have examined the long-term effects of EL. Tasks were not always trained in the patients' natural or home environment, limiting the external validity of these studies. This multicenter parallel randomized controlled trial examines the effects of EL compared with trial and error learning (TEL) on the performance of activities of daily living in persons with Alzheimer's or mixed-type dementia living at home. Methods: Patients received nine 1-hour task training sessions over eight weeks using EL or TEL. Task performance was measured using video observations at week 16. Secondary outcome measures were task performance measured at week 26, satisfaction with treatment, need for assistance, challenging behavior, adverse events, resource utilization and treatment costs. Results: A total of 161 participants were randomized, of whom 71 completed the EL and 74 the TEL arm at week 11. Sixty-nine EL patients and 71 TEL patients were assessed at the 16-week follow-up (the primary measurement endpoint). Intention-to-treat analysis showed a significantly improved task performance in both groups. No significant differences between the treatment groups were found for primary or secondary outcomes. Conclusions: Structured relearning improved the performance of activities of daily living. Improvements were maintained for 6 months. EL had no additional effect over TEL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Working memory binding and episodic memory formation in aging, mild cognitive impairment, and Alzheimer’s dementia.
- Author
-
van Geldorp, Bonnie, Heringa, Sophie M., van den Berg, Esther, Olde Rikkert, Marcel G. M., Biessels, Geert Jan, and Kessels, Roy P. C.
- Subjects
SHORT-term memory ,EPISODIC memory ,YOUNG adults ,MIDDLE-aged persons ,DEMENTIA research - Abstract
Introduction: Recent studies indicate that in both normal and pathological aging working memory (WM) performance deteriorates, especially when associations have to be maintained. However, most studies typically do not assess the relationship between WM and episodic memory formation. In the present study, we examined WM and episodic memory formation in normal aging and in patients with early Alzheimer’s disease (mild cognitive impairment, MCI; and Alzheimer’s dementia, AD). Method: In the first study, 26 young adults (mean age 29.6 years) were compared to 18 middle-aged adults (mean age 52.2 years) and 25 older adults (mean age 72.8 years). We used an associative delayed-match-to-sample WM task, which requires participants to maintain two pairs of faces and houses presented on a computer screen for short (3 s) or long (6 s) maintenance intervals. After the WM task, an unexpected subsequent associative memory task was administered (two-alternative forced choice). In the second study, 27 patients with AD and 19 patients with MCI were compared to 25 older controls, using the same paradigm as that in Experiment 1. Results: Older adults performed worse than both middle-aged and young adults. No effect of delay was observed in the healthy adults, and pairs that were processed during long maintenance intervals were not better remembered in the subsequent memory task. In the MCI and AD patients, longer maintenance intervals hampered the task performance. Also, both patient groups performed significantly worse than controls on the episodic memory task as well as the associative WM task. Conclusions: Aging and AD present with a decline in WM binding, a finding that extends similar results in episodic memory. Longer delays in the WM task did not affect episodic memory formation. We conclude that WM deficits are found when WM capacity is exceeded, which may occur during associative processing. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
20. Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study.
- Author
-
Olde Rikkert, Marcel G.M., Verhey, Frans R., Blesa, Rafael, von Arnim, Christine A.F., Bongers, Anke, Harrison, John, Sijben, John, Scarpini, Elio, Vandewoude, Maurits F.J., Vellas, Bruno, Witkamp, Renger, Kamphuis, Patrick J.G.H., and Scheltens, Philip
- Subjects
- *
ELEMENTAL diet , *SYNAPSES , *ALZHEIMER'S disease treatment , *MEMORY research , *COGNITION research - Abstract
Background: The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to improve synapse formation and function in patients with Alzheimer's disease (AD). Two double-blind randomized controlled trials (RCT) with Souvenaid of 12 and 24 week duration (Souvenir I and Souvenir II) showed that memory performance was improved in drug-naïve mild AD patients, whereas no effects on cognition were observed in a 24-week RCT (S-Connect) in mild to moderate AD patients using AD medication. Souvenaid was well-tolerated in all RCTs. Objective: In this 24-week open-label extension (OLE) study to the 24-week Souvenir II RCT, long-term safety and intake adherence of the medical food Souvenaid was evaluated. Methods: Patients with mild AD (n = 201) received Souvenaid once-daily during the OLE. Main outcome parameters were safety and product intake adherence. The memory domain z-score from a revised neuropsychological test battery was continued as exploratory parameter. Results: Compared to the RCT, a similar (low) incidence and type of adverse events was observed, being mainly (68.3%) of mild intensity. Pooled data (RCT and OLE) showed that 48-week use of Souvenaid was well tolerated with high intake adherence (96.1%). Furthermore, a significant increase in the exploratory memory outcome was observed in both the active-active and control-active groups during Souvenaid intervention. Conclusion: Souvenaid use for up to 48-weeks was well tolerated with a favorable safety profile and high intake adherence. The findings in this OLE study warrant further investigation toward the long-term safety and efficacy of Souvenaid in a well-controlled, double-blind RCT. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review.
- Author
-
Jekel, Katrin, Damian, Marinella, Wattmo, Carina, Hausner, Lucrezia, Bullock, Roger, Connelly, Peter J., Dubois, Bruno, Eriksdotter, Maria, Ewers, Michael, Graessel, Elmar, Kramberger, Milica G., Law, Emma, Mecocci, Patrizia, Molinuevo, José L., Nygård, Louise, Olde-Rikkert, Marcel G. M., Orgogozo, Jean-Marc, Pasquier, Florence, Peres, Karine, and Salmon, Eric
- Subjects
MILD cognitive impairment ,ALZHEIMER'S disease ,ACTIVITIES of daily living ,DEMENTIA ,COGNITIVE ability ,SYSTEMATIC reviews - Abstract
Introduction: There is a growing body of evidence that subtle deficits in instrumental activities of daily living (IADL) may be present in mild cognitive impairment (MCI). However, it is not clear if there are IADL domains that are consistently affected across patients with MCI. In this systematic review, therefore, we aimed to summarize research results regarding the performance of MCI patients in specific IADL (sub)domains compared with persons who are cognitively normal and/or patients with dementia. Methods: The databases PsycINFO, PubMed and Web of Science were searched for relevant literature in December 2013. Publications from 1999 onward were considered for inclusion. Altogether, 497 articles were retrieved. Reference lists of selected articles were searched for potentially relevant articles. After screening the abstracts of these 497 articles, 37 articles were included in this review. Results: In 35 studies, IADL deficits (such as problems with medication intake, telephone use, keeping appointments, finding things at home and using everyday technology) were documented in patients with MCI. Financial capacity in patients with MCI was affected in the majority of studies. Effect sizes for group differences between patients with MCI and healthy controls were predominantly moderate to large. Performance-based instruments showed slight advantages (in terms of effect sizes) in detecting group differences in IADL functioning between patients with MCI, patients with Alzheimer's disease and healthy controls. Conclusion: IADL requiring higher neuropsychological functioning seem to be most severely affected in patients with MCI. A reliable identification of such deficits is necessary, as patients with MCI with IADL deficits seem to have a higher risk of converting to dementia than patients with MCI without IADL deficits. The use of assessment tools specifically designed and validated for patients with MCI is therefore strongly recommended. Furthermore, the development of performance-based assessment instruments should be intensified, as they allow a valid and reliable assessment of subtle IADL deficits in MCI, even if a proxy is not available. Another important point to consider when designing new scales is the inclusion of technology-associated IADL. Novel instruments for clinical practice should be time-efficient and easy to administer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer's Disease.
- Author
-
Oosterveld, Saskia M., Kessels, Roy P.C., Hamel, Renske, Ramakers, Inez H.G.B., Aalten, Pauline, Verhey, Frans R.J., Sistermans, Nicole, Smits, Lieke L., Pijnenburg, Yolande A., van der Flier, Wiesje M., Olde Rikkert, Marcel G.M., and Melis, René J.F.
- Subjects
ALZHEIMER'S disease ,COMORBIDITY ,FRAGILITY (Psychology) ,ACTIVITIES of daily living ,COGNITIVE ability ,PSYCHOLOGY - Abstract
Co-morbidity and frailty are common in Alzheimer's disease (AD) and may contribute to the heterogeneity in clinical manifestations of the disease. We cross-sectionally investigated whether co-morbidity and frailty were independently associated with the clinical manifestation of AD in the 4C-Dementia study; a multicenter, longitudinal study in newly diagnosed AD patients. Clinical manifestation was operationalized using a composite of cognitive performance (neuropsychological assessment), activities of daily living (Disability Assessment for Dementia; DAD) and neuropsychiatric symptoms (Neuropsychiatric Inventory). As predictors of prime interest, co-morbidity was determined using the Cumulative Illness Rating Scale (CIRS-G) and frailty by the Fried criteria. In total, 213 AD patients participated (mean age 75 ± 10 years; 58% females). In linear regression models adjusted for age, gender, education, and disease duration, CIRS-G (β = -0.21, p < 0.01) and frailty (β = -0.34, p < 0.001) were separately associated with clinical AD manifestation. However, CIRS-G (β = -0.12, p = 0.12) lost statistical significance when both were combined (frailty: β = -0.31, p < 0.001). Models with the individual components of clinical AD manifestation as dependent variables show significant associations between cognitive performance and CIRS-G (β = -0.22, p = 0.01), and between DAD and frailty (β = -0.37, p < 0.001). Our findings indicate that physical health and clinical AD manifestation are associated. This association may be responsible for part of the heterogeneity in the presentation of AD. This emphasizes the importance of adequate assessment of co-morbid medical conditions and frailty in patients with AD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Differences in Nutritional Status Between Very Mild Alzheimer's Disease Patients and Healthy Controls.
- Author
-
Olde Rikkert, Marcel G.M., Verhey, Frans R., Sijben, John W.C., Bouwman, Femke H., Dautzenberg, Paul L.J., Lansink, Mirian, Sipers, Walther M.W., van Asselt, Dieneke Z.B., van Hees, Anneke M.J., Stevens, Martijn, Vellas, Bruno, and Scheltens, Philip
- Subjects
- *
ALZHEIMER'S disease , *ALZHEIMER'S patients , *FATTY acids , *ERYTHROCYTES , *CELL membranes , *NUTRITION - Abstract
Background: Studies on the systemic availability of nutrients and nutritional status in Alzheimer's disease (AD) are widely available, but the majority included patients in a moderate stage of AD. Objective: This study compares the nutritional status between mild AD outpatients and healthy controls. Methods: A subgroup of Dutch drug-naïve patients with mild AD (Mini-Mental State Examination (MMSE) ≥⃒20) from the Souvenir II randomized controlled study (NTR1975) and a group of Dutch healthy controls were included. Nutritional status was assessed by measuring levels of several nutrients, conducting the Mini Nutritional Assessment (MNA®) questionnaire and through anthropometric measures. Results: In total, data of 93 healthy cognitively intact controls (MMSE 29.0 [23.0-30.0]) and 79 very mild AD patients (MMSE = 25.0 [20.0-30.0]) were included. Plasma selenium (p < 0.001) and uridine (p = 0.046) levels were significantly lower in AD patients, with a similar trend for plasma vitamin D (p = 0.094) levels. In addition, the fatty acid profile in erythrocyte membranes was different between groups for several fatty acids. Mean MNA screening score was significantly lower in AD patients (p = 0.008), but not indicative of malnutrition risk. No significant differences were observed for other micronutrient or anthropometric parameters. Conclusion: In non-malnourished patients with very mild AD, lower levels of some micronutrients, a different fatty acid profile in erythrocyte membranes and a slightly but significantly lower MNA screening score were observed. This suggests that subtle differences in nutrient status are present already in a very early stage of AD and in the absence of protein/energy malnutrition. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
24. Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews.
- Author
-
van de Glind, Esther M.M., van Enst, Wynanda A., van Munster, Barbara C., Olde Rikkert, Marcel G.M., Scheltens, Philip, Scholten, Rob J.P.M., and Hooft, Lotty
- Subjects
ALZHEIMER'S disease ,CINAHL database ,DEMENTIA ,MENTAL depression ,DRUGS ,EXPERTISE ,INFORMATION storage & retrieval systems ,MEDICAL databases ,MEDICAL information storage & retrieval systems ,PSYCHOLOGY information storage & retrieval systems ,MEDICAL personnel ,MEDLINE ,SYSTEMATIC reviews ,EVIDENCE-based medicine ,AGITATION (Psychology) ,PROFESSIONAL practice ,CONCEPT mapping ,SYMPTOMS - Abstract
Background: Until now, multiple reviews on the pharmacological treatment of dementia have been published. Methods: We performed a scoping review to summarize research findings and to identify gaps in the existing literature. We searched the literature and assessed the risk of bias of the included reviews. A team of clinical experts assessed the fields in which more research is necessary. Fifty-five reviews with a low risk of bias were included, most of them concerning the treatment of cognitive decline (n = 16) and behavioral symptoms (n = 10) in Alzheimer's disease (AD). For cognitive impairment, cholinesterase inhibitors (n = 13) and memantine (n = 7) were described most frequently. Little information was found about the treatment of depression in dementia. Conclusions: For many current treatments, there is sufficient evidence. New research should focus on the symptomatic treatment of the earliest and most salient complaints in AD as well as on disease-modifying interventions acting at the level of the amyloid cascade. © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study.
- Author
-
Damian, Marinella, Hausner, Lucrezia, Jekel, Katrin, Richter, Melany, Froelich, Lutz, Almkvist, Ove, Boada, Merce, Bullock, Roger, De Deyn, Peter Paul, Frisoni, Giovanni B., Hampel, Harald, Jones, Roy W., Kehoe, Patrick, Lenoir, Hermine, Minthon, Lennart, Olde Rikkert, Marcel G.M., Rodriguez, Guido, Scheltens, Philip, Soininen, Hilkka, and Spiru, Luiza
- Subjects
ALZHEIMER'S disease risk factors ,CEREBROSPINAL fluid examination ,RESEARCH ,AMNESIA ,ANALYSIS of covariance ,ANALYSIS of variance ,BIOMARKERS ,CHI-squared test ,CLUSTER analysis (Statistics) ,CONFIDENCE intervals ,DISEASE susceptibility ,ENZYME-linked immunosorbent assay ,EPIDEMIOLOGY ,GENES ,LONGITUDINAL method ,MAGNETIC resonance imaging ,NEUROPSYCHOLOGICAL tests ,MEDICAL cooperation ,RESEARCH funding ,STATISTICS ,TEMPORAL lobe ,LOGISTIC regression analysis ,DATA analysis ,QUANTITATIVE research ,STATISTICAL models ,DESCRIPTIVE statistics - Abstract
Background/Aims: To identify prodromal Alzheimer's disease (AD) subjects using a data-driven approach to determine cognitive profiles in mild cognitive impairment (MCI). Methods: A total of 881 MCI subjects were recruited from 20 memory clinics and followed for up to 5 years. Outcome measures included cognitive variables, conversion to AD, and biomarkers (e.g. CSF, and MRI markers). Two hierarchical cluster analyses (HCA) were performed to identify clusters of subjects with distinct cognitive profiles. The first HCA included all subjects with complete cognitive data, whereas the second one selected subjects with very mild MCI (MMSE ≥28). ANOVAs and ANCOVAs were computed to examine whether the clusters differed with regard to conversion to AD, and to AD-specific biomarkers. Results: The HCAs identified 4-cluster solutions that best reflected the sample structure. One cluster (aMCIsingle) had a significantly higher conversion rate (19%), compared to subjective cognitive impairment (SCI, p < 0.0001), and non-amnestic MCI (naMCI, p = 0.012). This cluster was the only one showing a significantly different biomarker profile (Aβ
42 , t-tau, APOE ε4, and medial temporal atrophy), compared to SCI or naMCI. Conclusion: In subjects with mild MCI, the single-domain amnestic MCI profile was associated with the highest risk of conversion, even if memory impairment did not necessarily cross specific cut-off points. A cognitive profile characterized by isolated memory deficits may be sufficient to warrant applying prevention strategies in MCI, whether or not memory performance lies below specific z-scores. This is supported by our preliminary biomarker analyses. However, further analyses with bigger samples are needed to corroborate these findings. Copyright © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
26. A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer's Disease.
- Author
-
Hartmann, Tobias, van Wijk, Nick, Wurtman, Richard J., Olde Rikkert, Marcel G.M., Sijben, John W.C., Soininen, Hilkka, Vellas, Bruno, and Scheltens, Philip
- Subjects
PHOSPHOLIPIDS ,ALZHEIMER'S disease research ,BRAIN physiology ,NUTRITION research ,BLOOD lipids ,BIOMARKERS - Abstract
Recently, a biomarker panel of 10 plasma lipids, including 8 phosphatidylcholine species, was identified that could predict phenoconversion from cognitive normal aged adults to amnestic mild cognitive impairment or Alzheimer's disease (AD) within 2-3 years with >90% accuracy. The reduced levels of these plasma phospholipids could reflect altered phospholipid metabolism in the brain and periphery. We show that a 24-week nutritional intervention in drug-naïve patients with very mild to mild AD significantly increased 5 of the 7 measured biomarker phosphatidylcholine species. By providing nutrients which normally rate-limit phospholipid synthesis, this nutritional intervention could be useful in asymptomatic subjects with a plasma lipid biomarker profile prognostic of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. CEREBROSPINAL FLUID BIOMARKERS IN ALZHEIMER'S DISEASE: ARE THE HYPOTHESES MORE DYNAMIC THAN THE BIOMARKERS?
- Author
-
Spies, Petra E., Verbeek, Marcel M., Olde Rikkert, Marcel G.M., and Claassen, Jurgen A.H.R.
- Subjects
LETTERS to the editor ,ALZHEIMER'S disease - Abstract
A letter to the editor is presented regarding the use of cerebrospinal fluid as a biomarker in Alzheimer's disease.
- Published
- 2010
- Full Text
- View/download PDF
28. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial
- Author
-
Scheltens, Philip, Kamphuis, Patrick J.G.H., Verhey, Frans R.J., Olde Rikkert, Marcel G.M., Wurtman, Richard J., Wilkinson, David, Twisk, Jos W.R., and Kurz, Alexander
- Subjects
ELEMENTAL diet ,ALZHEIMER'S disease ,DRUG efficacy ,RANDOMIZED controlled trials ,DEMENTIA ,SYNAPSES ,VITAMINS ,OMEGA-3 fatty acids - Abstract
Abstract: Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer''s disease (AD). Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the delayed verbal recall task of the Wechsler Memory Scale–revised, and the 13-item modified Alzheimer''s Disease Assessment Scale–cognitive subscale at week 12. Results: At 12 weeks, significant improvement in the delayed verbal recall task was noted in the active group compared with control (P = .021). Modified Alzheimer''s Disease Assessment Scale–cognitive subscale and other outcome scores (e.g., Clinician Interview Based Impression of Change plus Caregiver Input, 12-item Neuropsychiatric Inventory, Alzheimer''s disease Co-operative Study–Activities of Daily Living, Quality of Life in Alzheimer''s Disease) were unchanged. The control group neither deteriorated nor improved. Compliance was excellent (95%) and the product was well tolerated. Conclusions: Supplementation with a medical food including phosphatide precursors and cofactors for 12 weeks improved memory (delayed verbal recall) in mild AD patients. This proof-of-concept study justifies further clinical trials. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
29. The need for systems thinking to advance Alzheimer's disease research.
- Author
-
Uleman, Jeroen F., Quax, Rick, Melis, René J.F., Hoekstra, Alfons G., and Olde Rikkert, Marcel G.M.
- Abstract
• Late-onset Alzheimer's disease involves interacting mechanisms across multiple scales. • Systems thinking addresses this complexity via conceptual and computational models. • Quantifying extensive models with data enables multi-factor intervention simulations. • Personalized multi-factor interventions: greater efficacy and synergistic benefits. • Systems thinking promotes knowledge synthesis, iterative model-driven data collection. Despite extensive research efforts to mechanistically understand late-onset Alzheimer's disease (LOAD) and other complex mental health disorders, curative treatments remain elusive. We emphasize the multiscale multicausality inherent to LOAD, highlighting the interplay between interconnected pathophysiological processes and risk factors. Systems thinking methods, such as causal loop diagrams and systems dynamic models, offer powerful means to capture and study this complexity. Recent studies developed and validated a causal loop diagram and system dynamics model using multiple longitudinal data sets, enabling the simulation of personalized interventions on various modifiable risk factors in LOAD. The results indicate that targeting factors like sleep disturbance and depressive symptoms could be promising and yield synergistic benefits. Furthermore, personalized interventions showed significant potential, with top-ranked intervention strategies differing significantly across individuals. We argue that systems thinking approaches can open new prospects for multifactorial precision medicine. In future research, systems thinking may also guide structured, model-driven data collection on the multiple interactions in LOAD's complex multicausality, facilitating theory development and possibly resulting in effective prevention and treatment options [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Genetic overlap between Alzheimer's disease and blood lipid levels.
- Author
-
van der Linden, Robert J., Reus, Lianne M., De Witte, Ward, Tijms, Betty M., Olde Rikkert, Marcel, Visser, Pieter Jelle, and Poelmans, Geert
- Subjects
- *
BLOOD lipids , *ALZHEIMER'S disease , *GENOME-wide association studies , *BLOOD diseases , *MONOGENIC & polygenic inheritance (Genetics) , *NEURAL transmission - Abstract
• Polygenic risk score-based screen for identifying shared genetic etiology. • There is genetic sharing between Alzheimer's disease and lipid levels in the blood. • Genetic concordance implies higher levels of specific lipids in Alzheimer's disease. • These results may be leveraged to develop novel therapeutic interventions. Late-onset Alzheimer's disease (AD) has a significant genetic component, but the molecular mechanisms through which genetic risk factors contribute to AD pathogenesis are unclear. We screened for genetic sharing between AD and the blood levels of 615 metabolites to elucidate how the polygenic architecture of AD affects metabolomic profiles. We retrieved summary statistics from genome-wide association studies of AD and the metabolite blood levels and assessed for shared genetic etiology, using a polygenic risk score-based approach. For the blood levels of 31 metabolites, all of which were lipids, we identified and replicated genetic sharing with AD. We also found a positive genetic concordance - implying that genetic risk factors for AD are associated with higher blood levels - for 16 of the 31 replicated metabolites. In the brain, lipids and their intermediate metabolites have essential structural and functional roles, such as forming and dynamically regulating synaptic membranes. Our results imply that genetic risk factors for AD affect lipid levels, which may be leveraged to develop novel treatment strategies for AD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Predicting Cognitive and Functional Trajectories in People With Late-Onset Dementia: 2 Population-Based Studies.
- Author
-
Haaksma, Miriam L., Rizzuto, Debora, Leoutsakos, Jeannie-Marie S., Marengoni, Alessandra, Tan, Edwin C.K., Olde Rikkert, Marcel G.M., Fratiglioni, Laura, Melis, René J.F., and Calderón-Larrañaga, Amaia
- Subjects
- *
DIAGNOSIS of dementia , *DEMENTIA prevention , *DEMENTIA risk factors , *AGE distribution , *GERIATRIC assessment , *ALZHEIMER'S disease , *COGNITIVE testing , *CONFIDENCE intervals , *COUNSELING , *DEMENTIA , *LONGITUDINAL method , *QUESTIONNAIRES , *RISK assessment , *SOCIAL networks , *STATISTICS , *COMORBIDITY , *LOGISTIC regression analysis , *ACTIVITIES of daily living , *STRUCTURAL equation modeling , *DISEASE progression , *ODDS ratio , *DELAYED onset of disease , *OLD age ,PREVENTION of disease progression - Abstract
Previous studies have shown large heterogeneity in the progression of dementia, both within and between patients. This heterogeneity offers an opportunity to limit the global and individual burden of dementia through the identification of factors associated with slow disease progression in dementia. We explored the heterogeneity in dementia progression to detect disease, patient, and social context factors related to slow progression. Two longitudinal population-based cohort studies with follow-up across 12 years. 512 people with incident dementia from Stockholm (Sweden) contributed to the Kungsholmen Project and the Swedish National Study of Aging and Care in Kungsholmen. We measured cognition using the Mini-Mental State Examination and daily functioning using the Katz Activities of Daily Living Scale. Latent classes of trajectories were identified using a bivariate growth mixture model. We then used bias-corrected logistic regression to identify predictors of slower progression. Two distinct groups of progression were identified; 76% (n = 394) of the people with dementia exhibited relatively slow progression on both cognition and daily functioning, whereas 24% (n = 118) demonstrated more rapid worsening on both outcomes. Predictors of slower disease progression were Alzheimer's disease (AD) dementia type [odds ratio (OR) 2.07, 95% confidence interval (CI) 1.15-3.71], lower age (OR 0.88, 95% CI 0.83-0.94), fewer comorbidities (OR 0.77, 95% CI 0.66-0.90), and a stronger social network (OR 1.72, 95% CI 1.01-2.93). Lower age, AD dementia type, fewer comorbidities, and a good social network appear to be associated with slow cognitive and functional decline. These factors may help to improve the counseling of patients and caregivers and to optimize the planning of care in dementia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Oscillations in cerebral blood flow and cortical oxygenation in Alzheimer's disease
- Author
-
van Beek, Arenda H.E.A., Lagro, Joep, Olde-Rikkert, Marcel G.M., Zhang, Rong, and Claassen, Jurgen A.H.R.
- Subjects
- *
ALZHEIMER'S disease , *CEREBROVASCULAR disease risk factors , *HYPERBARIC oxygenation , *CEREBROVASCULAR disease , *BLOOD pressure , *INFRARED spectroscopy - Abstract
Abstract: In Alzheimer''s disease (AD) cerebrovascular function is at risk. Transcranial Doppler, near-infrared spectroscopy, and photoplethysmography are noninvasive methods to continuously measure changes in cerebral blood flow velocity (CBFV), cerebral cortical oxygenated hemoglobin (O2Hb), and blood pressure (BP). In 21 patients with mild to moderate AD and 20 age-matched controls, we investigated how oscillations in cerebral blood flow velocity (CBFV) and O2Hb are associated with spontaneous and induced oscillations in blood pressure (BP) at the very low (VLF = 0.05 Hz) and low frequencies (LF = 0.1 Hz). We applied spectral and transfer function analysis to quantify dynamic cerebral autoregulation and brain tissue oxygenation. In AD, cerebrovascular resistance was substantially higher (34%, AD vs. control: Δ = 0.69 (0.25) mm Hg/cm/second, p = 0.012) and the transmission of very low frequency (VLF) cerebral blood flow (CBF) oscillations into O2Hb differed, with increased phase lag and gain (Δ phase 0.32 [0.15] rad; Δ gain 0.049 [0.014] μmol/cm/second, p both < 0.05). The altered transfer of CBF to cortical oxygenation in AD indicates that properties of the cerebral microvasculature are changed in this disease. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
33. Functional co-activation of the default mode network in APOE ε4-carriers: A replication study.
- Author
-
Mentink, Lara J., Guimarães, João P.O.F.T., Faber, Myrthe, Sprooten, Emma, Olde Rikkert, Marcel G.M., Haak, Koen V., and Beckmann, Christian F.
- Subjects
- *
DEFAULT mode network , *BRAIN anatomy , *FACE perception , *ALZHEIMER'S disease , *FAMILIES ,AGE factors in Alzheimer's disease - Abstract
Structural and functional alterations of the brain in persons genetically at-risk for Alzheimer's disease (AD) are crucial in unravelling AD development. Filippini et al. found that the default mode network (DMN) is already affected in young APOE ε4-carriers, with increased co-activation of the DMN during rest and increased hippocampal task activation. We aimed to replicate the early findings of Filippini et al, using the APOE gene, still the principal AD risk gene, and extended this with a polygenic risk score (PRS) analysis for AD, using the Human Connectome Project dataset (HCP). We included participants from the HCP S1200 dataset (age range: 22-36 years). We studied morphometric features, functional DMN co-activation and functional task activation of recollection performance. Permutation Analysis of Linear Models (PALM) was used to test for group differences between APOE ε4-carriers and non-carriers, and to test the association with PRS. PALM controls for biases induced by the family structure of the HCP sample. Results were family-wise error rate corrected at p < 0.05. Our primary analysis did not replicate the early findings of Filippini et al. (2009). However, compared with non-carriers, APOE ε4-carriers showed increased functional activation during the encoding of subsequently recollected items in areas related to facial recognition (p<0.05, t>756.11). This increased functional activation was also positively associated with PRS (APOE variants included) (p<0.05, t>647.55). Our results are supportive for none to limited genetic effects on brain structure and function in young adults. Taking the methodological considerations of replication studies into account, the true effect of APOE ε4-carriership is likely smaller than indicated in the Filippini paper. However, it still holds that we may not yet be able to detect already present measurable effects decades before a clinical expression of AD. Since the mechanistic pathway of AD is likely to encompass many different factors, further research should be focused on the interactions of genetic risk, biomarkers, aging and lifestyle factors over the life course. Sensitive functional neuroimaging as used here may help disentangling these complex interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study.
- Author
-
Haaksma, Miriam L., Rizzuto, Debora, Ramakers, Inez H.G.B., Garcia-Ptacek, Sara, Marengoni, Alessandra, van der Flier, Wiesje M., Verhey, Frans R.J., Olde Rikkert, Marcel G.M., and Melis, René J.F.
- Subjects
- *
DIAGNOSIS of dementia , *DEMENTIA , *REPORTING of diseases , *FRAIL elderly , *INSTITUTIONAL care , *LONGITUDINAL method , *REGRESSION analysis , *COMORBIDITY , *PROGNOSIS - Abstract
Abstract Objectives The predictive value of frailty and comorbidity, in addition to more readily available information, is not widely studied. We determined the incremental predictive value of frailty and comorbidity for mortality and institutionalization across both short and long prediction periods in persons with dementia. Design Longitudinal clinical cohort study with a follow-up of institutionalization and mortality occurrence across 7 years after baseline. Setting and Participants 331 newly diagnosed dementia patients, originating from 3 Alzheimer centers (Amsterdam, Maastricht, and Nijmegen) in the Netherlands, contributed to the Clinical Course of Cognition and Comorbidity (4C) Study. Measures We measured comorbidity burden using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) and constructed a Frailty Index (FI) based on 35 items. Time-to-death and time-to-institutionalization from dementia diagnosis onward were verified through linkage to the Dutch population registry. Results After 7 years, 131 patients were institutionalized and 160 patients had died. Compared with a previously developed prediction model for survival in dementia, our Cox regression model showed a significant improvement in model concordance (U) after the addition of baseline CIRS-G or FI when examining mortality across 3 years (FI: U = 0.178, P =.005, CIRS-G: U = 0.180, P =.012), but not for mortality across 6 years (FI: U = 0.068, P =.176, CIRS-G: U = 0.084, P =.119). In a competing risk regression model for time-to-institutionalization, baseline CIRS-G and FI did not improve the prediction across any of the periods. Conclusions Characteristics such as frailty and comorbidity change over time and therefore their predictive value is likely maximized in the short term. These results call for a shift in our approach to prognostic modeling for chronic diseases, focusing on yearly predictions rather than a single prediction across multiple years. Our findings underline the importance of considering possible fluctuations in predictors over time by performing regular longitudinal assessments in future studies as well as in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers
- Author
-
Slats, Diane, Claassen, Jurgen A.H.R., Spies, Petra E., Borm, George, Besse, Kees T.C., van Aalst, William, Tseng, Jack, Sjögren, Magnus J.C., Olde Rikkert, Marcel G.M., and Verbeek, Marcel M.
- Subjects
- *
ALZHEIMER'S disease , *CEREBROSPINAL fluid , *BIOMARKERS , *TAU proteins , *AMYLOID beta-protein , *THERAPEUTICS - Abstract
Abstract: Large hour-to-hour variability has previously been demonstrated in the cerebrospinal fluid (CSF) concentrations of Alzheimer''s disease (AD) biomarkers amyloid β42 (Aβ42) and Aβ40 in healthy younger subjects. We investigated the within-subject variability over 36 hours in CSF Aβ and tau proteins, in older subjects and AD patients. Six patients with mild stage AD (59–85 years, Mini Mental State Examination (MMSE) 16–26) and 6 healthy older volunteers (64–77 years) received an intrathecal catheter from which, during 36 hours, each hour 6 mL of CSF was drawn. Concentrations of Aβ42, Aβ40, total tau, and phosphorylated tau were determined and the variability was analyzed. Within-subject variability within 3-hour periods was assessed as the coefficient of variation, which was comparable for these 4 biomarkers in controls (4.2%–4.6%) and AD (3.1%–5.8%). Variability over 12 hour periods was 5.3% to 9.5%. These findings suggest that CSF biomarker variability is relatively low in healthy older controls and AD patients. Furthermore, continuous sampling of CSF proved to be a useful and robust method, which may also be used to investigate AD pathogenesis and to evaluate pharmacotherapeutic interventions. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.